TGFB1 and myeloproliferative disorder: An AURKA inhibitor MLN8237 (alisertib) was tested in the Jak2V617F and MPLW515L MPN models, and preferentially induced apoptosis and differentiation of mutant megakaryocytes, reduced TGF-β secretion, and improved bone marrow fibrosis73.